ALSUntangled # 69: astaxanthin

Timothy Fullam; Carmel Armon; Paul Barkhaus; Benjamin Barnes; Morgan Beauchamp; Michael Benatar; Tulio Bertorini; Robert Bowser; Mark Bromberg; Javier Mascias Cadavid; Gregory T. Carter; Mazen Dimachkie; Dave Ennist; Eva L. Feldman; Terry Heiman-patterson; Sartaj Jhooty; Isaac Lund; Christopher Mcdermott; Gary Pattee; Dylan Ratner; Paul Wicks; Richard Bedlack

doi:10.1080/21678421.2023.2171302

ALSUntangled # 69: astaxanthin

Timothy Fullam, Carmel Armon, Paul Barkhaus, Benjamin Barnes, Morgan Beauchamp, Michael Benatar, Tulio Bertorini, Robert Bowser, Mark Bromberg, Javier Mascias Cadavid, Gregory T. Carter, Mazen Dimachkie, Dave Ennist, Eva L. Feldman, Terry Heiman-patterson, Sartaj Jhooty, Isaac Lund, Christopher Mcdermott, Gary Pattee, Dylan RatnerPaul Wicks, Richard Bedlack^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

Abstract

ALSUntangled reviews alternative and off-label treatments for people living with amyotrophic lateral sclerosis (PALS). Here we review astaxanthin which has plausible mechanisms for slowing ALS progression including antioxidant, anti-inflammatory, and anti-apoptotic effects. While there are no ALS-specific pre-clinical studies, one verified “ALS reversal” occurred in a person using a combination of alternative therapies which included astaxanthin. There have been no trials of astaxanthin in people living with ALS. Natural astaxanthin appears to be safe and inexpensive. Based on the above information, we support further pre-clinical and/or clinical trials of astaxanthin in disease models and PALS, respectively, to further elucidate efficacy.

Original language	English
Pages (from-to)	553-557
Number of pages	5
Journal	Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration
Volume	24
Issue number	5-6
DOIs	https://doi.org/10.1080/21678421.2023.2171302
State	Published - 2023
Externally published	Yes

Keywords

Amyotrophic lateral sclerosis
alternative therapy
astaxanthin
neurodegeneration
oxidative stress

Access to Document

10.1080/21678421.2023.2171302

Cite this

Fullam, T., Armon, C., Barkhaus, P., Barnes, B., Beauchamp, M., Benatar, M., Bertorini, T., Bowser, R., Bromberg, M., Mascias Cadavid, J., Carter, G. T., Dimachkie, M., Ennist, D., Feldman, E. L., Heiman-patterson, T., Jhooty, S., Lund, I., Mcdermott, C., Pattee, G., ... Bedlack, R. (2023). ALSUntangled # 69: astaxanthin. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 24(5-6), 553-557. https://doi.org/10.1080/21678421.2023.2171302

@article{262e5d1aea3b4530b4abfce7adc48072,

title = "ALSUntangled # 69: astaxanthin",

abstract = "ALSUntangled reviews alternative and off-label treatments for people living with amyotrophic lateral sclerosis (PALS). Here we review astaxanthin which has plausible mechanisms for slowing ALS progression including antioxidant, anti-inflammatory, and anti-apoptotic effects. While there are no ALS-specific pre-clinical studies, one verified “ALS reversal” occurred in a person using a combination of alternative therapies which included astaxanthin. There have been no trials of astaxanthin in people living with ALS. Natural astaxanthin appears to be safe and inexpensive. Based on the above information, we support further pre-clinical and/or clinical trials of astaxanthin in disease models and PALS, respectively, to further elucidate efficacy.",

keywords = "Amyotrophic lateral sclerosis, alternative therapy, astaxanthin, neurodegeneration, oxidative stress",

author = "Timothy Fullam and Carmel Armon and Paul Barkhaus and Benjamin Barnes and Morgan Beauchamp and Michael Benatar and Tulio Bertorini and Robert Bowser and Mark Bromberg and {Mascias Cadavid}, Javier and Carter, {Gregory T.} and Mazen Dimachkie and Dave Ennist and Feldman, {Eva L.} and Terry Heiman-patterson and Sartaj Jhooty and Isaac Lund and Christopher Mcdermott and Gary Pattee and Dylan Ratner and Paul Wicks and Richard Bedlack",

note = "Publisher Copyright: {\textcopyright} 2023 World Federation of Neurology on behalf of the Research Group on Motor Neuron Diseases.",

year = "2023",

doi = "10.1080/21678421.2023.2171302",

language = "אנגלית",

volume = "24",

pages = "553--557",

journal = "Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration",

issn = "2167-8421",

publisher = "Informa Healthcare",

number = "5-6",

}

Fullam, T, Armon, C, Barkhaus, P, Barnes, B, Beauchamp, M, Benatar, M, Bertorini, T, Bowser, R, Bromberg, M, Mascias Cadavid, J, Carter, GT, Dimachkie, M, Ennist, D, Feldman, EL, Heiman-patterson, T, Jhooty, S, Lund, I, Mcdermott, C, Pattee, G, Ratner, D, Wicks, P & Bedlack, R 2023, 'ALSUntangled # 69: astaxanthin', Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, vol. 24, no. 5-6, pp. 553-557. https://doi.org/10.1080/21678421.2023.2171302

TY - JOUR

T1 - ALSUntangled # 69

T2 - astaxanthin

AU - Fullam, Timothy

AU - Armon, Carmel

AU - Barkhaus, Paul

AU - Barnes, Benjamin

AU - Beauchamp, Morgan

AU - Benatar, Michael

AU - Bertorini, Tulio

AU - Bowser, Robert

AU - Bromberg, Mark

AU - Mascias Cadavid, Javier

AU - Carter, Gregory T.

AU - Dimachkie, Mazen

AU - Ennist, Dave

AU - Feldman, Eva L.

AU - Heiman-patterson, Terry

AU - Jhooty, Sartaj

AU - Lund, Isaac

AU - Mcdermott, Christopher

AU - Pattee, Gary

AU - Ratner, Dylan

AU - Wicks, Paul

AU - Bedlack, Richard

PY - 2023

Y1 - 2023

N2 - ALSUntangled reviews alternative and off-label treatments for people living with amyotrophic lateral sclerosis (PALS). Here we review astaxanthin which has plausible mechanisms for slowing ALS progression including antioxidant, anti-inflammatory, and anti-apoptotic effects. While there are no ALS-specific pre-clinical studies, one verified “ALS reversal” occurred in a person using a combination of alternative therapies which included astaxanthin. There have been no trials of astaxanthin in people living with ALS. Natural astaxanthin appears to be safe and inexpensive. Based on the above information, we support further pre-clinical and/or clinical trials of astaxanthin in disease models and PALS, respectively, to further elucidate efficacy.

AB - ALSUntangled reviews alternative and off-label treatments for people living with amyotrophic lateral sclerosis (PALS). Here we review astaxanthin which has plausible mechanisms for slowing ALS progression including antioxidant, anti-inflammatory, and anti-apoptotic effects. While there are no ALS-specific pre-clinical studies, one verified “ALS reversal” occurred in a person using a combination of alternative therapies which included astaxanthin. There have been no trials of astaxanthin in people living with ALS. Natural astaxanthin appears to be safe and inexpensive. Based on the above information, we support further pre-clinical and/or clinical trials of astaxanthin in disease models and PALS, respectively, to further elucidate efficacy.

KW - Amyotrophic lateral sclerosis

KW - alternative therapy

KW - astaxanthin

KW - neurodegeneration

KW - oxidative stress

UR - http://www.scopus.com/inward/record.url?scp=85147227592&partnerID=8YFLogxK

U2 - 10.1080/21678421.2023.2171302

DO - 10.1080/21678421.2023.2171302

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???

C2 - 36694292

AN - SCOPUS:85147227592

SN - 2167-8421

VL - 24

SP - 553

EP - 557

JO - Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration

JF - Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration

IS - 5-6

ER -

ALSUntangled # 69: astaxanthin

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this